ES2099494T3 - Prolinamidas del acido fenilacetico sustituido con imidazolilo. - Google Patents

Prolinamidas del acido fenilacetico sustituido con imidazolilo.

Info

Publication number
ES2099494T3
ES2099494T3 ES94100845T ES94100845T ES2099494T3 ES 2099494 T3 ES2099494 T3 ES 2099494T3 ES 94100845 T ES94100845 T ES 94100845T ES 94100845 T ES94100845 T ES 94100845T ES 2099494 T3 ES2099494 T3 ES 2099494T3
Authority
ES
Spain
Prior art keywords
prolinamides
imidazolyl
phenylacetic acid
acid substituted
substituted phenylacetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94100845T
Other languages
English (en)
Inventor
Matthias Dr Muller-Gliemann
Jurgen Dr Dressel
Peter Dr Fey
Rudolf H Dr Hanko
Walter Dr Hubsch
Thomas Dr Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2099494T3 publication Critical patent/ES2099494T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

POLIAMIDAS DE ACIDO FENILACETICO SUSTITUIDAS POR IMIDAZOLILO SE OBTIENEN EN EL QUE LOS ACIDOS FENILACETICOS SUSTITUIDOS POR IMIDAZOLILO SE TRANSFORMAN CON PROLINAS. LAS POLINAMIDAS DE ACIDOS FENILACETICOS SUSTITUIDOS POR IMIDAZOLILO PUEDEN UTILIZARSE COMO SUSTANCIAS EN MEDICAMENTOS, PREFERENTEMENTE PARA EL TRATAMIENTO DE HIPERTONIA Y ARTEROESCLEROSIS.
ES94100845T 1993-02-03 1994-01-21 Prolinamidas del acido fenilacetico sustituido con imidazolilo. Expired - Lifetime ES2099494T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4302957A DE4302957A1 (de) 1993-02-03 1993-02-03 Imidazolyl-substituierte Phenylessigsäureprolinamide

Publications (1)

Publication Number Publication Date
ES2099494T3 true ES2099494T3 (es) 1997-05-16

Family

ID=6479487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94100845T Expired - Lifetime ES2099494T3 (es) 1993-02-03 1994-01-21 Prolinamidas del acido fenilacetico sustituido con imidazolilo.

Country Status (8)

Country Link
US (1) US5459156A (es)
EP (1) EP0610697B1 (es)
JP (1) JPH06271573A (es)
AT (1) ATE150018T1 (es)
DE (2) DE4302957A1 (es)
DK (1) DK0610697T3 (es)
ES (1) ES2099494T3 (es)
GR (1) GR3023194T3 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774236B1 (en) * 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
US7396846B2 (en) * 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US9845292B2 (en) * 2013-09-19 2017-12-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective FKBP51 ligands for treatment of psychiatric disorders
CN107001337B (zh) * 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ190995A (en) * 1978-09-05 1982-03-09 American Cyanamid Co Substituted omega propionyl or butyryl l-prolines and pharmaceutical compositions
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0515548A4 (en) * 1990-02-13 1993-03-10 Merck & Co. Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
DE4200954A1 (de) * 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
DE4208051A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Substituierte phenylessigsaeureamide
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists

Also Published As

Publication number Publication date
ATE150018T1 (de) 1997-03-15
DE4302957A1 (de) 1994-08-04
EP0610697A1 (de) 1994-08-17
GR3023194T3 (en) 1997-07-30
DK0610697T3 (da) 1997-09-15
EP0610697B1 (de) 1997-03-12
US5459156A (en) 1995-10-17
JPH06271573A (ja) 1994-09-27
DE59401990D1 (de) 1997-04-17

Similar Documents

Publication Publication Date Title
MY131595A (en) Heterocyclically substituted phenyl-cyclohexane- carboxylic acid derivatives
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
TW289020B (es)
RU94040170A (ru) Изохинолины
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
ATE164159T1 (de) Substituierte triole
ES2099494T3 (es) Prolinamidas del acido fenilacetico sustituido con imidazolilo.
BR9408392A (pt) Derivados de ácidos arilacéticos e sua utilização como fungicidas
DE68901105D1 (de) Alkensaeurederivate.
MY126362A (en) Novel pyrimido [1,2-a] indoles
EP0610698A3 (en) Substituted imidazo(4,5-b)pyridines and benzimidazoles as angiotensin ii antagonistes.
ATE160146T1 (de) Hetero-tricyclisch-substituierte phenyl- cyclohexan-carbonsäurederivate
FI956025A7 (fi) Menetelmä oksatsolidiinikarboksyylihapon valmistamiseksi, joka on hyödyllinen valmistettaessa terapeuttisesti vaikuttavia taksoideja
TW245713B (es)
AU8241091A (en) The use of formamidine sulfinic acid as an oxygen scavenger

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 610697

Country of ref document: ES